Furthermore, COVID-19 survivors demonstrated decreased circulating CD19+CD27− B cells compared to patients with a poor outcome in the acute stage of the disease, while the CD19+CD27+ B cell numbers in this group were lower compared to controls or patients with a poor outcome (Figure 4C,D). The gene discussed is CD27; the disease is COVID-19.